Clinical Utility of Targeted Next-Generation Sequencing for Determining Human Epidermal Growth Factor Receptor 2 Status and Optimizing Targeted Therapy in Breast Cancer
Targeted NGS has the potential in distinguishing HER2 IHC 3+, 2+, and 1+ tumors from IHC 0 in patients with BC; however, differentiating between HER2 IHC 1+ and 0 remains challenging. Additionally, targeted NGS may aid in the identification of actionable mutations, thereby contributing to the selection of optimal treatment strategies in BC management.
Authors
- Kazuki Moro (ORCID: https://orcid.org/0000-0002-6826-4374)
- Toshifumi Wakai (ORCID: https://orcid.org/0000-0003-2443-3428)
- Kana Naruse
- Hiroshi Ichikawa (ORCID: https://orcid.org/0000-0002-4445-2928)
- Yoshifumi Shimada (ORCID: https://orcid.org/0000-0003-0524-236X)
- Kazuaki Takabe (ORCID: https://orcid.org/0000-0002-6435-4241)
- Mika Sugai
- Shujiro Okuda (ORCID: https://orcid.org/0000-0002-7704-8104)
- Jun Tsuchida
- Yasuo Obata
- Yu Koyama (ORCID: https://orcid.org/0000-0001-9743-6473)
- Haruka Uchida
- Jun Sakata (ORCID: https://orcid.org/0000-0001-5790-6063)
- Hajime Umezu (ORCID: https://orcid.org/0000-0001-9033-2508)
- Hiroko Otake
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Zero to Three (US)
- Niigata University Medical and Dental Hospital (JP)
- University at Buffalo, State University of New York (US)
- Niigata University (JP)
Publication Details
- Journal
- World Journal of Oncology
- Published
- 2025-07-26
- DOI
- https://doi.org/10.14740/wjon2583
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00